Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease

Aging and Cognitive FunctionsDementia

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial

Lancet Neurol.

Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group

doi: 10.1016/

Targeting prodromal Alzheimer's disease: too late for prevention?

Lancet Neurol.

Yassine HN

doi: 10.1016/

Aging and Cognitive FunctionsAlzheimer’s Disease

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials

JAMA.

Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL

doi: 10.1001/jama.2017.20373.

Dementia

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Alzheimers Dement.

Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL, Kornhuber J, Reisberg B, Riedel-Heller SG, Risacher SL, Roehr S, Sachdev PS, Scarmeas N, Scheltens P, Shulman MB, Saykin AJ, Verfaillie SCJ, Visser PJ, Vos SJB, Wagner M, Wolfsgruber S, Jessen F; Alzheimer's Disease Neuroimaging Initiative, the DESCRIPA working group, the INSIGHT-preAD study group, on behalf of the SCD-I working group, van der Flier WM

doi: 10.1016/j.jalz.2018.10.003.

Alzheimer’s Disease

Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease

J Alzheimers Dis.

Brugnolo A, De Carli F, Pagani M, Morbelli S, Jonsson C, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzezga A, van Berckel BNM, Ossenkoppele R, Didic M, Guedj E, Arnaldi D, Massa F, Grazzini M, Pardini M, Mecocci P, Dottorini ME, Bauckneht M, Sambuceti G, Nobili F

doi: 10.3233/JAD-

Aging and Cognitive FunctionsAlzheimer’s DiseaseDementia

A phase 3 trial of IV immunoglobulin for Alzheimer disease

Neurology.

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study

doi: 10.1212/

Aging and Cognitive FunctionsAlzheimer’s Disease

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology

JAMA Neurol.

Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative

doi: 10.1001/jamaneurol.

Alzheimer’s Disease

I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies

JAMA Neurol.

Messmer MF, Wilhelm EE, Shoulson I

doi: 10.1001/

A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease